OCUP Ocuphire Pharma
- 1.760
- +0.060+3.53%
Ocuphire Pharma News
Ocuphire Pharma Is Maintained at Buy by Canaccord Genuity
Ocuphire Pharma Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Ocuphire Pharma, Lowers Price Target to $18
Canaccord Genuity analyst John Newman maintains Ocuphire Pharma with a Buy and lowers the price target from $22 to $18.
HC Wainwright & Co. : The Ocuphire Pharma (OCUP.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
HC Wainwright & Co. : The Ocuphire Pharma (OCUP.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price target.
Ocuphire Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 1076.47% HC Wainwright & Co. → $20 Reiterates Buy → Buy 03/20/2024 1076.47% Alliance Global Par
Buy Rating Affirmed: Ocuphire Pharma's APX3330 Shows Promise for Diabetic Retinopathy and Pipeline Progress
Ocuphire Pharma First Quarter 2024 Earnings: Misses Expectations
Ocuphire Pharma Gambles on Cash-Pay Strategy for RYZUMVI: Is It a Path to Profit or a Financial Pitfall?
Ocuphire Pharma Shares Updates in Upcoming Investor Meetings
Ocuphire Pharma | 10-Q: Quarterly report
Ocuphire Pharma Q1 2024 GAAP EPS $(0.29) Misses $(0.13) Estimate
Ocuphire Pharma (NASDAQ:OCUP) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.13) by 123.08 percent.
Ocuphire Pharma 1Q Loss $7.11M >OCUP
Ocuphire Pharma 1Q Loss $7.11M >OCUP
Ocuphire Pharma 1Q Loss/Shr 29c >OCUP
Ocuphire Pharma 1Q Loss/Shr 29c >OCUP
Ocuphire Pharma Had Cash and Cash Equivalents of $47.2M at March 31 >OCUP
Ocuphire Pharma Had Cash and Cash Equivalents of $47.2M at March 31 >OCUP
Press Release: Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clin
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Ocuphire Pharma to Present at the Aegis Virtual Conference
Ocuphire Pharma to Present at the Aegis Virtual Conference Download as PDF May 03, 2024 FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-st
Press Release: Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) ("Ocuphire"), a clinical-st
Ocuphire Pharma Incentivizes Director Pepose With Stocks and Options
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOntrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million. Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82%
Analysis
Price Target
No Data
